Intravitreal injection of KH902
KHSWKH902004
Phase 2 mab completed
Quick answer
Intravitreal injection of KH902 for Neovascular Age-related Macular Degeneration is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Neovascular Age-related Macular Degeneration
- Phase
- Phase 2
- Modality
- mab
- Status
- completed